Cyrus Harmon, Director at Olema Pharmaceuticals, Inc. (OLMA), sold 25,000 shares at $12.33 ($257K) on 2024-06-04, disclosed to the SEC on 2024-06-04.
Scheduled sale ($257k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.41 | 15,000 | $141K | 54.8% |
| 2 | $10.93 | 5,000 | $55K | 21.2% |
| 3 | $12.33 | 5,000 | $62K | 23.9% |
| Total | $10.30 avg | 25,000 | $257K | 100% |
| Filing → |
| OLMA | SELL | 2026-01-16 | $102K | — | Filing → |
| OLMA | SELL | 2025-12-29 | $164K | — | Filing → |
| OLMA | SELL | 2025-09-18 | $285K | — | Filing → |